Independent Allocation of Vaccines Group (IAVG)

The main purpose of the IAVG is to make validation assessments of proposals for Vaccine Allocation Decisions (“VAD proposals”), which outline the volumes of Vaccines that should be allocated to each country/economy participating under COVAX within a given time frame. The IAVG will consider VAD proposals prepared and submitted by the Joint Allocation Taskforce (“JAT”), composed of WHO and Gavi staff.

One of the principal objectives of COVAX is to promote the fair and equitable allocation of COVID-19 vaccines that are procured or distributed through COVAX (the “Vaccines”) to countries and economies participating in COVAX. To achieve such objective, the mechanism through which Vaccines are allocated must be transparent and independent.

In this context, WHO, Gavi and CEPI (collectively, the “COVAX Partners”) support the establishment by WHO of an Independent Allocation of Vaccines Group (“IAVG”) pursuant to the WHO Regulations for Study and Scientific Groups, Collaborating Institutions and Other Mechanisms of Collaboration, and in accordance with these Terms of Reference. The IAVG is expected to play a pivotal role in the allocation of Vaccines under COVAX and to foster the independence of, and provide transparency into, the Vaccine-allocation decision-making under COVAX.

The main purpose of the IAVG is to make validation assessments of proposals for Vaccine Allocation Decisions (“VAD proposals”), which outline the volumes of Vaccines that should be allocated to each country/economy participating under COVAX within a given time frame. The IAVG will consider VAD proposals prepared and submitted by the Joint Allocation Taskforce (“JAT”), composed of WHO and Gavi staff.

The IAVG will have the following functions:

1. To review the VAD proposals submitted by the JAT and to request clarifications from the JAT when necessary;
2. To discuss with the JAT any adjustments to the VAD proposals considered necessary on the basis of IAVG’s critical assessment;
3. To make validation assessments of the VAD proposals, ensuring they are technically informed and based on the latest available data and evidence;
4. For each VAD proposal that is validated by the IAVG (hereinafter a “VAD”), to document and justify the validation of such VAD, including any adjustments made to the original VAD proposal submitted to the IAVG by the JAT;
5. To deliver the VADs to the WHO Deputy-Director General for further implementation by the JAT.

The Allocation Mechanism for vaccines interacts directly with the COVAX facility

The JAT and IAVG formulate a vaccine allocation decision, passed on to COVAX facility for implementation

---

1. The allocation model then be passed to UNICEF SD or PAHO CD and vetted by participants.
2. Algorithm can be overlooked with a JAT validated.